5
Disease activity measurements and monitoring in psoriatic arthritis and axial spondyloarthritis

https://doi.org/10.1016/j.berh.2014.10.004Get rights and content

Abstract

In addition to the critical need of measuring tools for drug development of spondyloarthritis (SpA), these tools are also valuable for patient management. An early diagnosis, determination of early therapeutic response, and monitoring therapeutic response have now become increasingly important because effective therapies are available, and therapies such as anti-tumor necrosis factor (TNF) drugs are even more effective if used in early disease stages. In this review, we focus on disease activity measurements and monitoring in axial SpA and psoriatic arthritis (PsA). Both axial SpA and PsA have heterogeneous clinical manifestations. Therefore, in addition to the measurement of each clinical domain, composite measures inclusive of all clinical domains can be very helpful and are more likely to give complete and reliable information about the disease activity. A major focus of this review is to describe the recently developed composite measures for axial SpA and PsA.

Introduction

Spondyloarthritis (SpA) is a heterogeneous disease that can have either a predominantly axial or peripheral phenotype [1], ∗[2]. The range of clinical manifestations in SpA is broad and includes chronic (typically inflammatory) back pain, arthritis, enthesitis, dactylitis, and extra-articular features such as psoriasis, uveitis, inflammatory bowel disease, and fatigue. These manifestations may occur separately or simultaneously in the same patient or in their family members, and the disease is strongly linked to human leukocyte antigen B27 (HLA-B27) positivity [1], ∗[2].

Measuring and monitoring disease activity are of paramount importance in rheumatology and in medicine in general. Yet quantifying disease activity is a complex and challenging process. Composite scores can be particularly useful to measure disease activity because they integrate several different aspects of disease activity into one single numerical value, resulting in a more precise estimate of disease activity than the individual variables of the composite score. They also have the potential to increase the statistical power of clinical trials and observational studies. Furthermore, they improve the consistency of patient assessment and care across different clinical and research settings, and help patients and doctors better understand the disease and its impact. However, there may be times when measuring a specific disease feature may be more appropriate, because the therapeutic intervention may be directed primarily at a certain clinical manifestation and not necessarily aimed at generating a global change in disease activity [3], [4].

In this review, we focus on disease activity measurements and monitoring in axial SpA and in the most prevalent form of peripheral SpA, psoriatic arthritis (PsA). All the instruments described for axial SpA were initially developed for ankylosing spondylitis (AS) but are currently applied in both radiographic (i.e., AS) and non-radiographic axial SpA. Several concepts addressed in this review relate to the Outcome Measures in Rheumatology (OMERACT) filter [5], a set of criteria that can serve as a guide to develop valid and meaningful indices. The OMERACT filter includes aspects of “truth” (Is the measure truthful? Does it measure what it intends to measure? Is the result unbiased and relevant?), “discrimination” (Does the measure discriminate between situations that are of interest? Does the measure have the ability to detect change?), and “feasibility” (Can the measure be applied easily, given constraints of time, money, and interpretability?) [5].

Section snippets

Disease activity measurements and monitoring in axial SpA

The Assessment of SpondyloArthritis International Society (ASAS) has proposed several instruments to assess health outcomes in axial SpA. These instruments cover distinct domains and are divided into core sets to be applied in different settings (Table 1) ∗[2], [6]. These core sets include several disease activity variables such as the assessment of spinal pain, patient global assessment of disease activity, the number of swollen joints (with a 44-joint count being recommended), an enthesitis

Disease activity measurements and monitoring in PsA

PsA does not have diagnostic criteria. Currently, a widely used classification criteria for psoriasis is the Classification Criteria for Psoriatic Arthritis (CASPAR) [51]. In Table 4, the components of the CASPAR criteria are mentioned. Compared to RA where the major disease focus is peripheral arthritis, outcome measures need to cover several manifestations of PsA as mentioned in Table 4, thus making their derivation and validation arduous. PsA is a heterogeneous disease, characterized by

Summary

In PsA and axial SpA, several outcome measures are available for various health outcomes of these diseases, which include disease activity, physical function, mobility, and QOL. Several measures have been developed specifically to assess clinical disease activity. The majority of these measures have good evidence to support their use. The field of assessment of psoriatic PsA and axial SpA has rapidly evolved in the last 5 years, including the development of new composite disease activity

Competing interests

None.

Acknowledgments

PM is funded by a postdoctoral research fellowship award from the National Institute for Health Research (NIHR). This publication was supported by researchers at the NIHR University College London Hospitals Biomedical Research Centre. The views expressed are those of the author and not necessarily those of the National Health Service (NHS), the NIHR, or the Department of Health.

References (101)

  • J. Sieper et al.

    The Assessment of SpondyloArthritis International Society (ASAS) handbook: a guide to assess spondyloarthritis

    Ann Rheum Dis

    (2009)
  • P. Tugwell et al.

    A methodologic framework for developing and selecting endpoints in clinical trials

    J Rheumatol

    (1982)
  • D.M. van der Heijde et al.

    Validity of single variables and composite indices for measuring disease activity in rheumatoid arthritis

    Ann Rheum Dis

    (1992)
  • M. Boers et al.

    The OMERACT filter for outcome measures in rheumatology

    J Rheumatol

    (1998)
  • D. van der Heijde et al.

    Selection of instruments in the core set for DC-ART, SMARD, physical therapy, and clinical record keeping in ankylosing spondylitis. Progress report of the ASAS Working Group. Assessments in ankylosing spondylitis

    J Rheumatol

    (1999)
  • P. Machado et al.

    How to measure disease activity in axial spondyloarthritis?

    Curr Opin Rheumatol

    (2011)
  • S. Garrett et al.

    A new approach to defining disease status in ankylosing spondylitis: the bath ankylosing spondylitis disease activity index

    J Rheumatol

    (1994)
  • A. Spoorenberg et al.

    Measuring disease activity in ankylosing spondylitis: patient and physician have different perspectives

    Rheumatol (Oxford)

    (2005)
  • L. Heuft-Dorenbosch et al.

    The influence of peripheral arthritis on disease activity in ankylosing spondylitis patients as measured with the bath ankylosing spondylitis disease activity index

    Arthritis Rheum

    (2004)
  • I.H. Song et al.

    Comparison of the bath ankylosing spondylitis disease activity index and a modified version of the index in assessing disease activity in patients with ankylosing spondylitis without peripheral manifestations

    Ann Rheum Dis

    (2009)
  • S.D. Jones et al.

    The bath ankylosing spondylitis patient global score (BAS-G)

    Br J Rheumatol

    (1996)
  • C. Lukas et al.

    Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis

    Ann Rheum Dis

    (2009)
  • D. van der Heijde et al.

    ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis

    Ann Rheum Dis

    (2009)
  • D. van der Heijde et al.

    Sensitivity and discriminatory ability of the ankylosing spondylitis disease activity score in patients treated with etanercept or sulphasalazine in the ASCEND trial

    Rheumatol (Oxford)

    (2012)
  • G. Kilic et al.

    Comparison of ASDAS and BASDAI as a measure of disease activity in axial psoriatic arthritis

    Clin Rheumatol

    (2014 Jul 2)
  • Y.L. Au et al.

    Disease activity assessment in ankylosing spondylitis in a Chinese cohort: BASDAI or ASDAS?

    Clin Rheumatol

    (2014)
  • C. Popescu et al.

    Ankylosing spondylitis functional and activity indices in clinical practice

    J Med Life

    (2014)
  • C. Fernandez-Espartero et al.

    Validity of the ankylosing spondylitis disease activity score (ASDAS) in patients with early spondyloarthritis from the Esperanza programme

    Ann Rheum Dis

    (2014)
  • K.M. Fagerli et al.

    Selecting patients with ankylosing spondylitis for TNF inhibitor therapy: comparison of ASDAS and BASDAI eligibility criteria

    Rheumatol (Oxford)

    (2012)
  • S.J. Pedersen et al.

    Responsiveness of the ankylosing spondylitis disease activity score (ASDAS) and clinical and MRI measures of disease activity in a 1-year follow-up study of patients with axial spondyloarthritis treated with tumour necrosis factor alpha inhibitors

    Ann Rheum Dis

    (2010)
  • M. Xu et al.

    The ankylosing spondylitis disease activity score is a highly discriminatory measure of disease activity and efficacy following tumour necrosis factor-alpha inhibitor therapies in ankylosing spondylitis and undifferentiated spondyloarthropathies in China

    Rheumatol (Oxford)

    (2011)
  • S.Z. Aydin et al.

    Active disease requiring TNF-alpha-antagonist therapy can be well discriminated with different ASDAS sets: a prospective, follow-up of disease activity assessment in ankylosing spondylitis

    Clin Exp Rheumatol

    (2010)
  • K. Nas et al.

    Discrimination ability of ASDAS estimating disease activity status in patients with ankylosing spondylitis

    Int J Rheum Dis

    (2010)
  • L. Eder et al.

    Is ASDAS better than BASDAI as a measure of disease activity in axial psoriatic arthritis?

    Ann Rheum Dis

    (2010)
  • F. Salaffi et al.

    Fibromyalgia in patients with axial spondyloarthritis: epidemiological profile and effect on measures of disease activity

    Rheumatol Int

    (2014)
  • J.E. Paramarta et al.

    Efficacy and safety of adalimumab for the treatment of peripheral arthritis in spondyloarthritis patients without ankylosing spondylitis or psoriatic arthritis

    Ann Rheum Dis

    (2013)
  • P. Machado et al.

    Ankylosing spondylitis disease activity score (ASDAS): defining cut-off values for disease activity states and improvement scores

    Ann Rheum Dis

    (2011)
  • J.J. Anderson et al.

    Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis

    Arthritis Rheum

    (2001)
  • J. Brandt et al.

    Development and preselection of criteria for short term improvement after anti-TNF alpha treatment in ankylosing spondylitis

    Ann Rheum Dis

    (2004)
  • C. Rodriguez-Lozano et al.

    Patient-acceptable symptom state as an outcome measure in the daily care of patients with ankylosing spondylitis

    J Rheumatol

    (2012)
  • G. Wariaghli et al.

    Evaluation and stability of the patient acceptable symptom state (PASS) over time in patients with ankylosing spondylitis

    Clin Exp Rheumatol

    (2012)
  • J. Braun et al.

    Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebo- controlled GO-RAISE study

    Ann Rheum Dis

    (2012)
  • J. Sieper et al.

    Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1)

    Ann Rheum Dis

    (2013)
  • X. Baraliakos et al.

    Long-term outcome of patients with active ankylosing spondylitis with etanercept-sustained efficacy and safety after seven years

    Arthritis Res Ther

    (2013)
  • A. Ciurea et al.

    Tumor necrosis factor alpha inhibition in radiographic and nonradiographic axial spondyloarthritis: results from a large observational cohort

    Arthritis Rheum

    (2013)
  • I.H. Song et al.

    Consistently good clinical response in patients with early axial spondyloarthritis after 3 years of continuous treatment with etanercept: longterm data of the ESTHER trial

    J Rheumatol

    (2014 Oct)
  • D. van der Heijde et al.

    The effect of golimumab therapy on disease activity and health-related quality of life in patients with ankylosing spondylitis: 2-year results of the GO-RAISE trial

    J Rheumatol

    (2014)
  • D. Poddubnyy et al.

    Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS)

    Ann Rheum Dis

    (2014)
  • P.M. Machado et al.

    Endorsement of definitions of disease activity states and improvement scores for the ankylosing spondylitis disease activity Score: results from OMERACT 10

    J Rheumatol

    (2011)
  • S.J. Pedersen et al.

    ASDAS, BASDAI and different treatment responses and their relation to biomarkers of inflammation, cartilage and bone turnover in patients with axial spondyloarthritis treated with TNFalpha inhibitors

    Ann Rheum Dis

    (2011)
  • Cited by (0)

    View full text